Evidence map›Paper›PMID 27042335›Full record

ReviewRMD open2016

Glucocorticoids and chronotherapy in rheumatoid arthritis.

Maurizio Cutolo

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in RMD open, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03911336 (Harnessing Chronomodulation to Enhance Osteogenesis - A Pilot Randomized Controlled Trial -), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03911336 phase4withdrawnnot on this mapstarted 2023, after this paper: background citation

Harnessing Chronomodulation to Enhance Osteogenesis - A Pilot Randomized Controlled Trial -

TypeinterventionalSponsorUniversity of IowaRan2023 to 2023Enrolled0ConditionsTooth LossArmsGroup A - test:Tooth extraction and intake of NSAID and a non-NSAID, Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID, Group C - Control 2: tooth extraction and intake of a Non-Nsaid
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Circadian pain patterns in human pain conditions - A systematic review.Pain practice : the official journal of World Institute of Pain · 2023
    Pooled it
  2. Circadian Modulation of the Antioxidant Effect of Grape Consumption: A Randomized Controlled Trial.International journal of environmental research and public health · 2023
    Trial
  3. Review
  4. Programmable chronogenetic gene circuits for self-regulated circadian delivery of biologic drugs.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Circadian Regulation of Macrophages and Osteoclasts in Rheumatoid Arthritis.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Circadian Variation in Efficacy of Medications.Clinical pharmacology and therapeutics · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Maurizio CutoloResearch Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine , University of Genova , Genova , Italy.
University of Genoa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is evident that the morning symptoms of rheumatoid arthritis (RA) are linked to the circadian abnormal increase in night inflammation, favoured by inadequate cortisol secretion under conditions of active disease. Therefore, exogenous glucocorticoid treatment is recommended in RA at low doses since it may partially act like a 'replacement therapy'. The prevention/treatment of the night upregulation of the immune/inflammatory reaction (and related flare of cytokine synthesis) has been shown to be more effective when exogenous glucocorticoid administration is obtained with a night-time-release formulation. Large-scale trials documented that modified-release prednisone has greater efficacy then morning prednisone for long-term low-dose glucocorticoid treatment in patients with RA, showing at least a more significant reduction in morning joint stiffness. Interestingly, despite a considerably higher cost than conventional prednisone, chronotherapy with night-time-release prednisone was recognised as a cost-effective option for patients with RA not on glucocorticoids who are eligible for therapy with biological disease-modifying antirheumatic drugs (DMARDs). Moreover, since different cell populations involved in the inflammatory process are particularly activated during the night, other therapeutical approaches used in RA, for example, conventional DMARDs and non-steroidal anti-inflammatory drugs (NSAIDs), should follow the same concepts of glucocorticoid chronotherapy. Indeed, bedtime methotrexate chronotherapy was found to improve RA symptoms compared to the current standard dosing methods, and several available NSAIDs (ie, indomethacin, aceclofenac, ketoprofen, flurbiporfen, lornoxicam) have been very recently modified in their formulation, in order to obtain chronotherapeutical effects in RA.

Indexed as

CorticosteroidsDMARDs (synthetic)InflammationNSAIDsRheumatoid Arthritis

Identifiers

PMID27042335
PMCPMC4800804
OpenAlexW2319800350

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.